Three Phase 3
readouts. One
still-dominant product.
✦ The bottom line
NovoCure's main risks aren't cash. They're clinical (three Phase 3 trials whose results decide future indications), commercial (insurance reimbursement is the gating constraint), and concentration (Optune Gio still dominates revenue).
↓ the brief below
From the 10-K · the reimbursement risk
[Our success depends on] our ability to secure and maintain adequate coverage from third-party payers to reimburse us for our Products for current and future indications.
↳ NovoCure tells you plainly: what insurers pay is the gating variable. Each new indication requires a new reimbursement fight. Each region of the world is its own coverage battle.
What 'binary trial outcome' looks like for NovoCure
Three Phase 3 trials are reading out in the next 12 months: TRIDENT (glioblastoma) in Q2 2026; KEYNOTE D58 (newly diagnosed GBM, with Merck) completes enrollment in Q4 2026; the FDA PMA decision on NSCLC brain metastases also in Q4 2026. Each is a binary catalyst. A success expands the addressable market and the valuation; a failure removes a planned product from the roadmap.
Wall Street calls this
Catalyst risk
Even profitable medical-device companies can swing 30%+ on a single Phase 3 readout. NovoCure has three of these queued up.
The concentration · product mix
95
%
Optune Gio still represents roughly 95% of active TTFields patients. Until Optune Lua and Optune Pax scale up materially, NovoCure's revenue is effectively one product.
Our success depends substantially on the commercial success of our Products. … We have invested significant resources in [research and development] activities to expand our product offering. We may not be able to grow revenues by expanding our product offerings.
↳ NovoCure has invested in expansion — but warns that the investment may not deliver. The phase 3 trials are the test of whether expansion happens.